Product Description
Zyceva 150mg Tablet is a prescription-only oral anticancer medicine containing Erlotinib, a targeted therapy (EGFR tyrosine kinase inhibitor) from Zydus Lifesciences. It is prescribed by oncologists for non-small cell lung cancer (NSCLC) and, in combination with gemcitabine, for advanced pancreatic cancer. It must be used only under the supervision of a qualified doctor.
Key Benefits
Targeted therapy that blocks EGFR signals that drive cancer cell growth
Prescribed for non-small cell lung cancer (NSCLC) and, with gemcitabine, for metastatic pancreatic cancer
Not a conventional chemotherapy medicine; it belongs to the kinase inhibitor class
Convenient once-daily oral tablet, as directed by the oncologist
Manufactured by Zydus Lifesciences Limited, India
Key Ingredients & Their Uses
Erlotinib Hydrochloride (equivalent to Erlotinib 150mg): reversibly blocks EGFR (HER1) tyrosine kinase activity, which stops the signals that make cancer cells grow and spread.
How to Use
Take exactly as prescribed by your oncologist, for as long as advised. Do not change the dose or stop on your own.
Take on an empty stomach, at least 1 hour before or 2 hours after a meal.
Swallow the tablet whole with water. Do not crush or split unless your doctor says so.
If you need an antacid or similar medicine, keep a gap of at least 2 hours after taking Zyceva, or as your doctor advises.
If you miss a dose, take it as soon as you remember. Do not double the dose.
Technical Specifications
Brand: Zyceva
Product Name: Zyceva 150mg Tablet
Composition: Erlotinib Hydrochloride 163.9mg equivalent to Erlotinib 150mg
Product Type: Prescription Allopathic Medicine (Anticancer, Tyrosine Kinase Inhibitor)
Net Quantity: 30 Tablets
Pack Type: Bottle (30 tablets)
Tablet Description: White to off-white, round, film-coated, debossed "915"
Storage: Room temperature, away from light and moisture
Suitable For: Adults, as prescribed by a doctor
Country of Origin: India
Manufacturer: Zydus Lifesciences Limited
